Spots Global Cancer Trial Database for crc
Every month we try and update this database with for crc cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Colorectal Cancer (CRC) Surveillance Tool: Cognitive and Pilot Testing | NCT03180411 | Colorectal Canc... | Interview Questionnaire | 18 Years - | M.D. Anderson Cancer Center | |
| A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors | NCT05668585 | Solid Tumors Melanoma NSCLC CRC ATC | CFT1946 Trametinib Cetuximab | 18 Years - | C4 Therapeutics, Inc. | |
| A Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors | NCT05571839 | Cutaneous Melan... Non-small Cell ... Colorectal Neop... Pancreatic Neop... Mesothelioma | SGN-BB228 | 18 Years - | Seagen Inc. | |
| A Phase III Clinical Study of Napabucasin (GB201) Plus FOLFIRI in Adult Patients With Metastatic Colorectal Cancer | NCT03522649 | Previously Trea... | Napabucasin Fluorouracil Leucovorin Irinotecan | 18 Years - | 1Globe Biomedical Co., Ltd. | |
| Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC) | NCT05233332 | CRC | HL-085 Vemurafenib | 18 Years - 80 Years | Shanghai Kechow Pharma, Inc. | |
| A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors | NCT06131840 | Colorectal Neop... Carcinoma, Non-... Stomach Neoplas... Pancreatic Duct... Gastroesophagea... Small Cell Lung... | SGN-CEACAM5C | 18 Years - | Seagen Inc. | |
| A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours | NCT05605522 | Pancreatic Duct... Squamous Cell C... Colorectal Canc... Gastric Cancer Ewing Sarcoma NTSR1 Expressin... Neuroendocrine ... | [225]-FPI-2059 [111In]-FPI-205... | 18 Years - | Fusion Pharmaceuticals Inc. | |
| Colorectal Cancer Umbrella Protocol - Assessment of Targeted Therapies Against Colorectal Cancer (ATTACC Program) Screening Protocol | NCT01196130 | Colorectal Canc... | Cancer Symptom ... Biomarker Testi... | 18 Years - | M.D. Anderson Cancer Center | |
| Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | NCT05358249 | KRAS G12C Mutan... Carcinoma, Non-... Carcinoma, Non-... Non-Small Cell ... Non-Small Cell ... Nonsmall Cell L... Colorectal Canc... Colorectal Carc... Colorectal Neop... Colorectal Tumo... Neoplasms, Colo... | JDQ443 trametinib Ribociclib cetuximab | 18 Years - | Novartis | |
| A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g) | NCT00851136 | Metastatic Colo... | bevacizumab FOLFOX PRO95780 | 18 Years - | Genentech, Inc. | |
| Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation | NCT05737706 | Solid Tumor Advanced Solid ... Non-small Cell ... Colo-rectal Can... Pancreatic Aden... | MRTX1133 | 18 Years - | Mirati Therapeutics Inc. | |
| FIH Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation in China | NCT05009329 | NSCLC CRC Solid Tumor | JAB-21822 JAB-21822 | 18 Years - | Jacobio Pharmaceuticals Co., Ltd. | |
| Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors | NCT04557449 | Liposarcoma CRC Prostate Cancer Breast Neoplasm... Adenocarcinoma ... Solid Tumors | PF-07220060 Letrozole Fulvestrant Midazolam Enzalutamide | 18 Years - | Pfizer | |
| Screening for Familial Colorectal Cancer (CRC) Patients | NCT00632515 | Colorectal Canc... | Questionnaire | - 60 Years | M.D. Anderson Cancer Center | |
| Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before Surgery | NCT06262581 | DMMR Colorectal... Anti PD-1 Immunotherapy | Tisleizumab(BGB... | 18 Years - | Sun Yat-sen University | |
| JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation | NCT05002270 | Advanced Solid ... NSCLC CRC | JAB-21822 (KRAS... JAB-21822 (KRAS... JAB-21822 (KRAS... Cetuximab (EGFR... | 18 Years - | Jacobio Pharmaceuticals Co., Ltd. | |
| Prevention of Colorectal Cancer Through Multiomics Blood Testing | NCT04369053 | Colon Cancer Rectal Cancer Colon Neoplasm Colon Diseases Colon Lesion Colon Polyp Colorectal Canc... Polyp Adenoma Rectal Diseases Gastrointestina... | Freenome test | 45 Years - 85 Years | Freenome Holdings Inc. | |
| FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER) | NCT05432193 | Pancreatic Duct... Colorectal Canc... Esophageal Canc... Melanoma (Skin) Soft Tissue Sar... Head and Neck S... Cholangiocarcin... | [Ga-68]-PNT6555 [Lu-177]-PNT655... | 18 Years - | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | |
| Colon Cancer Screening in First-Degree Relatives of Hispanic Colorectal Cancer (CRC) Patients | NCT00838318 | Colorectal Canc... | Interview | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers | NCT05544929 | Carcinoma, Non-... Cutaneous Melan... Carcinoma, Rena... Carcinoma, Ovar... Nasopharyngeal ... Carcinoma, Thym... Anal Cancer Mesothelioma Esophagogastric... High Microsatel... Squamous Cell C... Triple Negative... | KFA115 pembrolizumab | 18 Years - | Novartis | |
| Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before Surgery | NCT06262581 | DMMR Colorectal... Anti PD-1 Immunotherapy | Tisleizumab(BGB... | 18 Years - | Sun Yat-sen University | |
| A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors | NCT05538130 | Melanoma Glioma Thyroid Cancer Non-Small Cell ... Malignant Neopl... Brain Neoplasms Colorectal Canc... | PF-07799544 PF-07799933 encorafenib | 16 Years - | Pfizer | |
| A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat | NCT02890069 | Colorectal Canc... | PDR001 LCL161 Everolimus Panobinostat QBM076 HDM201 | 18 Years - | Novartis | |
| AI-EMERGE: Development and Validation of a Multi-analyte, Blood-based Colorectal Cancer Screening Test | NCT03688906 | Colo-rectal Can... Cancer Colon Cancer, Rectum Neoplasms,Color... Polyps Polyp of Colon Adenoma Adenoma Colon | 18 Years - | Freenome Holdings Inc. | ||
| A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors | NCT04913285 | Solid Tumor, Ad... Non-small Cell ... Melanoma | KIN-2787 KIN-2787 and bi... | 18 Years - | Pierre Fabre Medicament | |
| A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g) | NCT00851136 | Metastatic Colo... | bevacizumab FOLFOX PRO95780 | 18 Years - | Genentech, Inc. | |
| Study of DC-CIK to Treat Colorectal Cancer | NCT01839539 | Colorectal Canc... | dendritic and c... | 18 Years - | Guangxi Medical University | |
| A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat | NCT02890069 | Colorectal Canc... | PDR001 LCL161 Everolimus Panobinostat QBM076 HDM201 | 18 Years - | Novartis | |
| PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer | NCT03176264 | Metastatic Colo... | PDR001 bevacizumab mFOLFOX6 | 18 Years - | Novartis | |
| Engaging Black Men in Colorectal Cancer Screening | NCT05980182 | Colorectal Canc... CRC Behavior | mHealth Applica... | 45 Years - 74 Years | Virginia Commonwealth University | |
| Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma | NCT01394939 | Colorectal Carc... CRC | JX-594 Irinotecan | 18 Years - | SillaJen, Inc. | |
| Dendritic Cell Vaccination in Patients With Lynch Syndrome or Colorectal Cancer With MSI | NCT01885702 | Colorectal Canc... | DC vaccination | 18 Years - 75 Years | Radboud University Medical Center | |
| A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer | NCT04322539 | Metastatic Colo... Metastatic Colo... | Fruquintinib Placebo | 18 Years - | Hutchmed | |
| Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer | NCT03081494 | Metastatic Colo... | spartalizumab (... regorafenib | 18 Years - | Novartis | |
| Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer | NCT04046445 | Colorectal Canc... MSS Stage IV Colon ... Stage IV Rectal... Metastatic Colo... Liver Metastasi... | ATP128 BI 754091 VSV-GP128 | 18 Years - | Amal Therapeutics | |
| A Beta-only IL-2 ImmunoTherapY Study | NCT05086692 | Advanced Solid ... Unresectable So... Clear Cell Rena... Triple Negative... Non-Small Cell ... Non-Small Cell ... Colorectal Canc... Gastric Cancer Cervical Cancer Basal Cell Carc... Bladder Cancer Merkel Cell Car... Squamous Cell C... Cutaneous Squam... Pleural Mesothe... Esophageal Canc... Endometrial Car... Solid Tumor Solid Tumor, Ad... MSI-H Solid Mal... Cancer With A H... Epithelial Ovar... Primary Periton... Gastroesophagea... Acral Melanoma Mucosal Melanom... Cutaneous Melan... DMMR Solid Mali... Fallopian Tube ... Ovarian Cancer MSI-H Cancer DMMR Cancer Pancreas Adenoc... Skin Cancer | MDNA11 Pembrolizumab | 18 Years - | Medicenna Therapeutics, Inc. | |
| A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer | NCT03597581 | Gastrointestina... Gastrointestina... Colorectal Canc... Colorectal Neop... Colorectal Carc... Gastric Cancer Gastric Neoplas... KRAS Mutation-R... CRC Colorectal Canc... | ompenaclid FOLFIRI Bevacizumab FOLFOX regimen | 18 Years - | Inspirna, Inc. | |
| Addressing Colorectal Cancer in South Florida Firefighters | NCT05976282 | Colorectal Canc... CRC | Fecal Immunoche... Septin9 Test | 40 Years - 65 Years | University of Miami | |
| The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment | NCT04984369 | CRC | HLX208 Cetuximab Injec... | 18 Years - | Shanghai Henlius Biotech | |
| Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL) | NCT00628238 | Chronic Lymphoc... CLL Untreated Front-line First-Line Initial Therapy | Lenalidomide an... Lenalidomide an... | - | Chronic Lymphocytic Leukemia Research Consortium | |
| A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer | NCT05253651 | Colorectal Neop... | tucatinib trastuzumab bevacizumab cetuximab oxaliplatin leucovorin levoleucovorin fluorouracil | 18 Years - | Seagen Inc. | |
| A Study in Second Line Metastatic Colorectal Cancer | NCT01183780 | Colorectal Canc... | Ramucirumab Placebo Irinotecan Folinic Acid 5-Fluorouracil | 18 Years - | Eli Lilly and Company | |
| Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | NCT05379985 | Non-small Cell ... Colorectal Canc... Pancreatic Duct... Advanced Solid ... | RMC-6236 | 18 Years - | Revolution Medicines, Inc. | |
| A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies | NCT05957367 | Colorectal Canc... GIST | DCC-3116 Ripretinib Cetuximab Encorafenib | 18 Years - | Deciphera Pharmaceuticals LLC | |
| Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14) | NCT04975256 | Advanced Cancer Metastatic Canc... Malignant Neopl... Malignant Neopl... Malignant Neopl... | MRTX849 BI 1701963 | 18 Years - | Mirati Therapeutics Inc. | |
| Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before Surgery | NCT06262581 | DMMR Colorectal... Anti PD-1 Immunotherapy | Tisleizumab(BGB... | 18 Years - | Sun Yat-sen University | |
| A Study of Famitinib in Patients With Advanced Colorectal Cancer | NCT01762293 | Colorectal Canc... Colorectal Canc... Colorectal Canc... | Famitinib placebo | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| A Prospective Study Into the Risk of Colorectal Neoplasms in Individuals With a Family History of Advanced Adenomas (Sibling AN Study) | NCT01593098 | Adenoma CRC | 40 Years - 70 Years | Chinese University of Hong Kong | ||
| Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL) | NCT00628238 | Chronic Lymphoc... CLL Untreated Front-line First-Line Initial Therapy | Lenalidomide an... Lenalidomide an... | - | Chronic Lymphocytic Leukemia Research Consortium | |
| A Study of PRO95780 in Combination With Cetuximab and Irinotecan Chemotherapy or the FOLFIRI Regimen With Bevacizumab in Patients With Previously Treated Metastatic Colorectal Cancer (APM4187g) | NCT00497497 | Colorectal Canc... | bevacizumab cetuximab FOLFIRI regimen irinotecan PRO95780 | 18 Years - | Genentech, Inc. | |
| Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor | NCT06105021 | Pancreatic Duct... Non-Small Cell ... Colorectal Canc... Solid Tumor KRAS G12V | AFNT-211 | 18 Years - | Affini-T Therapeutics, Inc. | |
| A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors | NCT03665285 | Advanced or Met... Lung Cancer Breast Cancer Head and Neck S... Endometrial Can... Melanoma CRC Urothelial Carc... Cholangiocarcin... | NC318 | 18 Years - | NextCure, Inc. | |
| Improving Colorectal Cancer Screening for Diverse Hispanics in Urban Primary Care | NCT01569620 | Colorectal Canc... | Best clinical p... Best clinical p... Best clinical p... | 50 Years - 85 Years | Icahn School of Medicine at Mount Sinai | |
| Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy | NCT04868773 | Colorectal Canc... Colorectal Carc... Metastatic Canc... CRC | Cabozantinib TAS-102 | 18 Years - 100 Years | University of California, Irvine | |
| Prospective Trial to Compare the Clinical Efficiency of G-EYE™ HD Colonoscopy With Standard HD Colonoscopy | NCT01917513 | Adenoma Polyps Colorectal Canc... | G-EYE™ colonosc... Standard Colono... | 50 Years - | Smart Medical Systems Ltd. | |
| Study to Evaluate D-1553 in Subjects With Solid Tumors | NCT04585035 | Solid Tumor, Ad... NSCLC CRC | D-1553 D-1553 in combi... | 18 Years - | InventisBio Co., Ltd | |
| A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer | NCT00636610 | Metastatic Colo... | Vismodegib 150 ... Placebo to vism... Bevacizumab Modified FOLFOX FOLFIRI | 18 Years - | Genentech, Inc. | |
| A Phase 1/2 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway | NCT05578092 | Solid Tumor Advanced Solid ... Non Small Cell ... Colo-rectal Can... | MRTX0902 MRTX849 | 18 Years - | Mirati Therapeutics Inc. | |
| A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours | NCT02521844 | Solid Tumors | ETC-1922159 Pembrolizumab | 18 Years - | EDDC (Experimental Drug Development Centre), A*STAR Research Entities | |
| Colorectal Cancer (CRC) Surveillance Tool: Cognitive and Pilot Testing | NCT03180411 | Colorectal Canc... | Interview Questionnaire | 18 Years - | M.D. Anderson Cancer Center | |
| Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors | NCT03485209 | Colorectal Neop... Carcinoma, Non-... Exocrine Pancre... Carcinoma, Squa... | tisotumab vedot... pembrolizumab carboplatin cisplatin | 18 Years - | Seagen Inc. | |
| SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies | NCT05039944 | Colorectal Canc... | SI-B001 Irinotecan FOLFIRI Protoco... FOLFOX Protocol | 18 Years - | Sichuan Baili Pharmaceutical Co., Ltd. | |
| Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours | NCT04808362 | Advanced Solid ... Pancreatic Canc... CRC | OMO-103 | 18 Years - | Peptomyc S.L. | |
| A Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer | NCT05167409 | Microsatellite ... | Evorpacept (ALX... Cetuximab Pembrolizumab | 18 Years - | University of Colorado, Denver | |
| Study of NGR-hTNF as Single Agent in Patients Affected by Colorectal Cancer (CRC) | NCT00483080 | Colorectal Canc... | NGR-hTNF | 18 Years - 80 Years | AGC Biologics S.p.A. | |
| Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors | NCT03875313 | Solid Tumor Clear Cell Rena... TNBC - Triple-N... Colorectal Canc... CRC RCC ccRCC | CB-839 Talazoparib | 18 Years - | Calithera Biosciences, Inc | |
| Intratumoral Budding (ITB) in Preoperative Biopsies of Colon and Rectal Cancer | NCT03336658 | CRC | 18 Years - | Insel Gruppe AG, University Hospital Bern | ||
| Study of DC-CIK to Treat Colorectal Cancer | NCT01839539 | Colorectal Canc... | dendritic and c... | 18 Years - | Guangxi Medical University | |
| Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | NCT05358249 | KRAS G12C Mutan... Carcinoma, Non-... Carcinoma, Non-... Non-Small Cell ... Non-Small Cell ... Nonsmall Cell L... Colorectal Canc... Colorectal Carc... Colorectal Neop... Colorectal Tumo... Neoplasms, Colo... | JDQ443 trametinib Ribociclib cetuximab | 18 Years - | Novartis | |
| Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC | NCT06195670 | CRC Metastatic Colo... Metastatic Colo... | Experimental Active Comparat... | 18 Years - 85 Years | Zhejiang Cancer Hospital | |
| Phase II Study of Minocycline for Reducing Symptom Burden in Colorectal Patients | NCT01906008 | Colorectal Canc... | Minocycline Placebo Questionnaires Sensory Test | 18 Years - | M.D. Anderson Cancer Center | |
| A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors | NCT05538130 | Melanoma Glioma Thyroid Cancer Non-Small Cell ... Malignant Neopl... Brain Neoplasms Colorectal Canc... | PF-07799544 PF-07799933 encorafenib | 16 Years - | Pfizer | |
| Phase 1 and 2 Study of PX-866 and Cetuximab | NCT01252628 | Incurable Metas... Incurable Progr... | PX-866 (SCCHN) Cetuximab (SCCH... PX-866 (CRC) Cetuximab (CRC) | 18 Years - | Seagen Inc. | |
| A Retrospective Protocol Empowering Precision Research in Colorectal Cancer (ALFAOMEGA-RETRÒ) | NCT05101382 | Colorectal Canc... | Observation | 18 Years - | IFOM ETS - The AIRC Institute of Molecular Oncology | |
| Donation of Post Mortem Tumor Tissues | NCT03385980 | NSCLC Stage IV CRC CUP | Proteomic analy... | - | Niguarda Hospital | |
| Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers | NCT04430738 | Colorectal Carc... Gastric Adenoca... GEJ Adenocarcin... Esophageal Aden... Cholangiocarcin... Gallbladder Car... | tucatinib trastuzumab oxaliplatin leucovorin fluorouracil capecitabine pembrolizumab | 18 Years - | Seagen Inc. | |
| Azacitidine and CAPOX in Metastatic Colorectal Cancer | NCT01193517 | Colorectal Canc... | Azacitidine Capecitabine Oxaliplatin Azacitidine MTD | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer | NCT04844073 | Squamous Cell C... Non-small Cell ... Colorectal Canc... | TAK-186 | 18 Years - | Takeda | |
| A Study in Second Line Metastatic Colorectal Cancer | NCT01183780 | Colorectal Canc... | Ramucirumab Placebo Irinotecan Folinic Acid 5-Fluorouracil | 18 Years - | Eli Lilly and Company | |
| Diagnostic Value of Diffusion-weighted Magnetic Resonance in High-risk Colorectal and Appendiceal Neoplasms | NCT05623787 | Peritoneal Carc... Peritoneal Meta... Appendix Cancer Appendix Neopla... Colorectal Canc... | Whole-body diff... | 18 Years - | Laval University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
